We welcome your feedback and / or questions related to the
educational content provided through GuidelineStat™ Colon Cancer.
Release date:
May 22, 2009
Expiration date:
May 22, 2010
Click here to view Technical Requirements
Accreditation
This learning activity has been designated for 1.50 AMA PRA Category 1 Credits™.
Physicians should only claim credit commensurate with the extent of their participation in this activity.
Target Audience
This learning activity is intended for a broad audience of healthcare practitioners, including medical oncologists, primary care physicians, family physicians, specialists, nurse practitioners, and physician assistants.
Learning Objectives
After completing this educational activity, the learner should be better able to:
- List the criteria for appropriate selection of patients with stage II colon cancer for adjuvant therapy and also select the most appropriate adjuvant regimens for patients with stage III colon cancer.
- Explain the methods of post-treatment surveillance and decide which types of follow-up screening are appropriate for patients who have completed adjuvant therapy
- Discuss the standards of care for patients with advanced colon cancer, including determining the most effective and appropriate sequences of chemotherapeutic agents and combinations
- Compare and contrast the various first-line regimens currently available for metastatic colon cancer
- Describe the role of targeted agents in advanced colorectal cancer
- Determine an optimal schedule for supportive care in the management of relapsed metastatic disease
- Identify promising new agents in the treatment of colorectal cancer
- Discuss the role of various imaging options and biomarkers in the monitoring of patients with advanced colorectal cancer
- Review the developing criteria for determining patient suitability for resection
- Compare differences in treatments depending on whether the liver metastasis is resectable and understand the complications that may arise as a result of these treatments
Author
John L. Marshall, MD
Chief, Hematology and Oncology
Georgetown University
Associate Director
Clinical Research
Lombardi Comprehensive Cancer Center
Washington, DC
Disclosure of Financial Interests
As an accredited provider of continuing medical education, Imedex, LLC is required to ask authors to disclose any real or apparent conflict of interest they may have as related to the content of their chapter(s). The existence of commercial or financial interests of speakers related to the subject matter of their chapter(s) should not be construed as implying bias or decreasing the value of their chapter(s). However, the disclosure should help participants form their own judgments.
All authors were independently selected by the organizing committee.
Those authors who disclosed affiliations or financial interests with the
commercial organizations involved with products, to which they may refer are listed below.
- grant research
- consultant
- speaker's bureau
- stock shareholder
- other support
Dr John L. Marshall
Supporters of this activity:
Genentech3
Other affiliations:
Amgen3
Pfizer3
Roche3
sanofi aventis3
Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Specialty Group, which is a subsidiary of AmerisourceBergen Company. All Imedex staff members, except for the following, who are in a position to control the content of this activity, have no financial relationships with any commercial interests that are relevant to this activity:
Keith Steward, MD, MBA, owns shares of Pfizer Inc and Johnson & Johnson, as well as stock options for AmerisourceBergen.
Chris Bolwell owns shares of GlaxoSmithKline and stock options for AmerisourceBergen.
Bradley Bongiovanni, ND, Becky Lynch, RN, Emily Geiger, and Don Harting, MA, ELS own stock options for AmerisourceBergen.
Imedex, LLC is an independent provider of continuing medical education. Imedex, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA has regulatory authority.
Disclosure of Unapproved Uses and Investigational Drugs
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
Statement of Commercial Support
The following company has provided an unrestricted educational grant in support of this activity: Genentech
(*Please check this box to proceed - required)
|